| Role of macrophage targeting in the antitumor activity of trabectedin G Germano, R Frapolli, C Belgiovine, A Anselmo, S Pesce, M Liguori, ... Cancer cell 23 (2), 249-262, 2013 | 905 | 2013 |
| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 560 | 2017 |
| Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells G Germano, R Frapolli, M Simone, M Tavecchio, E Erba, S Pesce, ... Cancer research 70 (6), 2235-2244, 2010 | 303 | 2010 |
| α1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients C Gambacorti-Passerini, M Zucchetti, D Russo, R Frapolli, M Verga, ... Clinical cancer research 9 (2), 625-632, 2003 | 279 | 2003 |
| The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo D Brunelli, M Tavecchio, C Falcioni, R Frapolli, E Erba, R Iori, P Rollin, ... Biochemical pharmacology 79 (8), 1141-1148, 2010 | 158 | 2010 |
| Mode of action of trabectedin in myxoid liposarcomas S Di Giandomenico, R Frapolli, E Bello, S Uboldi, SA Licandro, S Marchini, ... Oncogene 33 (44), 5201-5210, 2014 | 141 | 2014 |
| Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models C Belgiovine, E Bello, M Liguori, I Craparotta, L Mannarino, L Paracchini, ... British journal of cancer 117 (5), 628-638, 2017 | 135 | 2017 |
| Tumor-associated macrophages and anti-tumor therapies: complex links C Belgiovine, M D’Incalci, P Allavena, R Frapolli Cellular and Molecular Life Sciences 73, 2411-2424, 2016 | 133 | 2016 |
| Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials GM Sulaiman, KW Al Sammarrae, AH Ad’hiah, M Zucchetti, R Frapolli, ... Food and Chemical Toxicology 49 (9), 2415-2421, 2011 | 123 | 2011 |
| G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors C Leonetti, M Scarsella, G Riggio, A Rizzo, E Salvati, M D'Incalci, ... Clinical Cancer Research 14 (22), 7284-7291, 2008 | 103 | 2008 |
| Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat S Donald, RD Verschoyle, P Greaves, TW Gant, T Colombo, M Zaffaroni, ... Cancer Research 63 (18), 5902-5908, 2003 | 88 | 2003 |
| The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus R Vázquez, ME Riveiro, L Astorgues-Xerri, E Odore, K Rezai, E Erba, ... Oncotarget 8 (5), 7598, 2017 | 87 | 2017 |
| Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging S Giordano, M Zucchetti, A Decio, M Cesca, I Fuso Nerini, M Maiezza, ... Scientific reports 6 (1), 39284, 2016 | 73 | 2016 |
| 3D mass spectrometry imaging reveals a very heterogeneous drug distribution in tumors S Giordano, L Morosi, P Veglianese, SA Licandro, R Frapolli, M Zucchetti, ... Scientific reports 6 (1), 37027, 2016 | 72 | 2016 |
| Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104) M Romano, R Frapolli, M Zangarini, E Bello, L Porcu, CM Galmarini, ... International journal of cancer 133 (9), 2024-2033, 2013 | 70 | 2013 |
| Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response M Cesca, L Morosi, A Berndt, IF Nerini, R Frapolli, P Richter, A Decio, ... Molecular cancer therapeutics 15 (1), 125-135, 2016 | 66 | 2016 |
| Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP‐1 and TIMP‐2 and tumor thrombospondin‐1 R Dossi, R Frapolli, S Di Giandomenico, L Paracchini, F Bozzi, S Brich, ... International Journal of Cancer 136 (3), 721-729, 2015 | 66 | 2015 |
| Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells C Belgiovine, R Frapolli, K Bonezzi, I Chiodi, F Favero, M Mello-Grand, ... PloS one 5 (11), e14154, 2010 | 59 | 2010 |
| Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel M Martinelli, K Bonezzi, E Riccardi, E Kuhn, R Frapolli, M Zucchetti, ... British journal of cancer 97 (7), 888-894, 2007 | 57 | 2007 |
| OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations ME Riveiro, L Astorgues-Xerri, R Vazquez, R Frapolli, I Kwee, A Rinaldi, ... Oncotarget 7 (51), 84675, 2016 | 56 | 2016 |
Massimo ZucchettiIstituto di Ricerche Farmacologiche Mario Negri IrVerified email at marionegri.it
